Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effects

Pediatric Pulmonology

Volumn 47, Issue 7, 2012, Pages 658-665

  Wilms, Erik B ^a   Touw, Daniel J ^b   Heijerman, Harry G M ^b   Van Der Ent, Cornelis K ^c  

^a Central Hospital Pharmacy   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

azithromycin maintenance therapy; cystic fibrosis; dosing schedule; pediatric dosage, neonatal dosage; pharmacokinetics

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; CYCLOSPORIN; DESLORATADINE; DORNASE ALFA; ERYTHROMYCIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; ROXITHROMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; BRONCHUS SECRETION; CYSTIC FIBROSIS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERANCE; HUMAN; LUNG DISEASE; LUNG FIBROSIS; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; WHEEZING;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; HUMANS; META-ANALYSIS AS TOPIC; PNEUMONIA, BACTERIAL;

EID: 84862184691     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21620     Document Type: Review

References (51)

1. Jaffé A, Francis J, Rosenthal M, Bush A,. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
2. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J,. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax 2002; 57: 212-216.
3. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M,. Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-984.
4. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003; 290: 1749-1756.
5. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP,. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006; 61: 895-902.
6. McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S,. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007; 30: 487-495.
7. Kabra SK, Pawaiya R, Lodha R, Kapil A, Kabra M, Vani AS, Agarwal G, Shastri SS,. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial. J Cyst Fibros 2010; 9: 17-23.
8. Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S,. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008; 102: 1643-1653.
9. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008-1012.
10. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2010; 303: 1707-1715.
11. Southern KW, Barker PM, Solis-Moya A, Patel L,. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004 (update 2011).
12. Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, HÃiby N,. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother 2007; 51: 3677-3687.
13. HÃiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A,. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3: 23-35.
14. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van Delden C,. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45: 1930-1933.
15. Kai T, Tateda K, Kimura S, Ishii Y, Ito H, Yoshida H, Kimura T, Yamaguchi K,. A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa. Pulm Pharmacol Ther 2009; 22: 483-486.
16. Wagner T, Soong G, Sokol S, Saiman L, Prince A,. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 2005; 128: 912-919.
17. Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL,. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 2007; 42: 533-541.
18. Tateda K, Ishii Y, Matsumoto T, Kobayashi T, Miyazaki S, Yamaguchi K,. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: Suppression of virulence factors and stress response. J Infect Chemother 2000; 6: 1-7.
19. Tamaoki J, Kadota J, Takizawa H,. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117: 5S-11S.
20. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P,. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006; 350: 977-982.
21. Gladue RP, Bright GM, Isaacson RE, Newborg MF,. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277-282.
22. Hand WL, Hand DL,. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents. 2001; 18: 419-425.
23. Foulds G, Shepard RM, Johnson RB,. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25: 73-82.
24. SpC Zithromax, Nov 2005, Pfizer Bv. Capelle aan den IJssel the Netherlands.
25. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 5013-5017.
26. Fassbender M, Lode H, Schiller C, Andro R, Goetschi B, Borner K, Koeppe P,. Comparative pharmacokinetics of macrolide antibiotics and concentrations achieved in polymorphonuclear leukocytes and saliva. Clin Microbiol Infect 1996; 1: 235-243.
27. Wilms E, Touw D, Heijerman H,. Pharmacokinetics of azithromycin in plasma, whole blood, polymorphonuclear neutrophils and sputum during chronic use in patients with cystic fibrosis. Ther Drug Monit 2006; 28: 219-225.
28. Cipolli M, Cazzola G, Novelli A, Cassatta MI, Fallani S, Mazzei T,. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest 2001; 21: 353-360.
29. Baumann U, King M, App EM, Tai S, König A, Fischer JJ, Zimmermann T, Sextro W, von der Hardt H, Long term azithromycin therapy in cystic fibrosis patients: A study on drug levels and sputum properties. Can Respir J 2004; 11: 151-155.
30. Wilms EB, Touw DJ, Heijerman HG,. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J Cyst Fibros 2008; 7: 79-84.
31. Jacobs RF, Maples HD, Aranda JV, Espinoza GM, Knirsch C, Chandra R, Fisher JM, Kearns GL,. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J 2005; 24: 34-39.
32. Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ,. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993; 37: 314-316.
33. Blandizzi C, Malizia T, Batoni G, Ghelardi E, Baschiera F, Bruschini P, Senesi S, Campa M, Del Tacca M,. Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. Antimicrob Agents Chemother 2002; 46: 1594-1596.
34. Florescu DF, Murphy PJ, Kalil AC,. Effects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis. Pulm Pharmacol Ther 2009; 22: 467-472.
35. Wallace MR, Miller LK, Nguyen MT, Shields AR,. Ototoxicity with azithromycin. Lancet 1994; 343: 241.
36. Phaff SJ, Tiddens HA, Verbrugh HA, Ott A,. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006; 57: 741-746.
37. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK,. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: Long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007; 26: 8-12.
38. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011. 121: 3554-3563.
39. Yeates RA, Laufen H, Zimmermann T, Schumacher T,. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int J Clin Pharmacol Ther 1997; 35: 577-579.
40. Pai MP, Graci DM, Amsden GW,. Macrolide drug interactions: An update. Ann Pharmacother 2000; 34: 495-513.
41. Granowitz EV, Tabor KJ, Kirchhoffer JB,. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000; 23: 1433-1435.
42. Huang BH, Wu CH, Hsia CP, Yin Chen C,. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 2007; 30: 1579-1582.
43. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD,. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007; 18: 243-246.
44. Russo V, Puzio G, Siniscalchi N,. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006; 77: 30-32.
45. Ripoll L, Reinert P, Pépin LF, Lagrange PH,. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother 1996; 37: 987-991.
46. Sanders NN, Franckx H, De Boeck K, Haustraete J, De Smedt SC, Demeester J,. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax 2006; 61: 962-968.
47. Amsden GW, Kuye O, Wei GC,. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002; 42: 444-449.
48. Strandell J, Bate A, Hägg S, Edwards IR,. Rhabdomyolysis a result of azithromycin and statins: An unrecognized interaction. Br J Clin Pharmacol 2009; 68: 427-434.
49. Mori T, Aisa Y, Nakazato T, Yamazaki R, Ikeda Y, Okamoto S,. Tacrolimus-azithromycin interaction in a recipient of allogeneic bone marrow transplantation. Transpl Int 2005; 18: 757-758.
50. Page RL II, Ruscin JM, Fish D, Lapointe M,. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001; 21: 1436-1443.
51. Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V,. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebo-controlled, parallel-group study. Clin Ther 2001; 23: 451-466.